Experience

Davis Polk advised the representatives of the underwriters in connection with the $345 million initial public offering of 14,375,000 shares of common stock of Atea Pharmaceuticals, Inc.,…

Davis Polk advised the joint book-running managers and representatives of the underwriters in connection with the follow-on offering of 3,506,098 shares of common stock of Allakos Inc…

Davis Polk advised the joint book-running managers and representatives of the several underwriters on the $72 million initial public offering by Biodesix, Inc. The common stock is listed on…

Davis Polk advised the representatives of the initial purchasers in connection with a Rule 144A/Regulation S offering by MPH Acquisition Holdings LLC, a wholly owned subsidiary of MultiPlan…

Davis Polk advised the joint book-running managers in connection with a $460 million SEC-registered common stock offering by Turning Point Therapeutics, Inc. The common stock is listed…

Davis Polk advised the representatives of the several underwriters in connection with Abcam plc’s $180 million U.S. initial public offering of 10,287,000 American depositary shares…

Davis Polk advised Xspray Pharma AB (publ) on a private placing of new shares. The private placing raised gross proceeds of approximately SEK 265 million.  Xspray was founded in 2003…

Davis Polk advised  the representatives of the several underwriters in connection with the $150 million initial public offering of 10,000,000 shares of common stock of Aligos…

Davis Polk advised the representatives of the several underwriters in connection with an initial public offering of 9,029,629 shares of common stock of Eargo, Inc. at $18.00 per share …

Davis Polk advised Royalty Pharma plc and the selling shareholders on Royalty Pharma’s $728 million secondary offering of 17,343,037 of its Class A ordinary shares by certain selling…